To the content
3 . 2021

Gliadomorphin, casomorphin, and intestinal fatty acid binding protein in children with autism spectrum disorders

Abstract

Diet therapy for autism spectrum disorders (ASD) remains one of the most popular alternative therapies. despite conflicting opinions regarding the effectiveness of the dietary approach. According to the theory of exorphin intoxication, gluten and casein peptides enter the bloodstream through the mucous membrane of the small intestine, penetrate the blood-brain barrier and affect the neurons of the cerebral cortex. The well-known hypothesis of the relationship between autism and gluten intolerance is based on this theory.

The aim of this work was to study the correlation between the blood concentration of intestinal fatty acid - binding protein (I-FABP) and gliadomorphin and casomorphin as markers of opioid intoxication, depending on the use of diet therapy in children with ASD.

Material and methods. The study included 85 patients aged 3 to 15 years with an established diagnosis of ASD. The first group consisted of 36 children who followed a gluten-free diet (GFD) for at least 6 months, 3 of them also followed a casein-free diet (CFD), the second group included 49 patients with ASD who had no dietary restrictions. The concentration of I-FABP, gliadomorphin, and casomorphin in the blood serum was determined by enzyme immunoassay in all patients.

Results. In children with ASD who followed GDD, the average values of the studied parameters were significantly lower than in patients with ASD who have no dietary restrictions: gliadomorphine - 0.98±1.27 vs 1.68±0.97 ng/ml, casomorphine - 1.62± 0.76 vs 2.37±0.53 pg/ml, I-FABP - 156.2±102.16 vs 528.26±255.95 pg/ml (p<0.01). In patients with ASD using diet therapy, there was a significant increase in gliadomorifin (r=0.64, p=0.0001) and casomorphin (r=0.53, p=0.001) with an increase in I-FABP. In children with ASD, not adhering GFD, there was also an increase in blood gliadomorphin (r=0.30, p=0.036) with an increase in I-FABP level; this trend was not observed relative to casomorphin (r=-0.0050, p=0.973). Perhaps, with the expansion of the sample, this pattern will also be observed in children who are on a regular diet.

Conclusion. When including diet therapy in the therapeutic treatment of autism, it is necessary to take into account the individual intolerance to gluten and casein, conduct additional examinations in order to specify the nature of the intolerance and the need to prescribe a diet.

Keywords:autism spectrum disorders, gluten-free diet, casein-free diet, gliadomorphin, casomorphin, intestinal fatty acid binding protein

Funding. The co-author of the article (I.A. Bavykina) is a scholar of the President of the Russian Federation for 2019-2021 for young scientists and graduate students carrying out promising research and development in priority areas of modernization of the Russian economy.

Conflict of interest. The authors declare no obvious and potential conflicts of interest related to the publication of this article.

For citation: Bavykina I.A., Popov V.I., Zvyagin A.A., Bavykin D.V. Gliadomorphin, casomorphin, and intestinal fatty acid binding protein in children with autism spectrum disorders. Voprosy pitaniia [Problems of Nutrition]. 2021; 90 (3): 20-7. DOI: https://doi.org/10.33029/0042-8833-2021-90-3-20-27 (in Russian)

References

1. Autism spectrum disorders. URL: https://www.who.int/mediacentre/factsheets/autism-spectrum disorders/ru (date of access June 6, 2018)

2. Vinogradova K.N. Etiology of autistic spectrum disorders. Sovremennaya zarubezhnaya psikhologiya [Modern Foreign Psychology]. 2014; 3 (4): 112–31. (in Russian)

3. Bavykina I.A., Zvyagin A.A., Nastausheva T.L. gluten Intolerance and autism spectrum disorders: a pathological tandem? Voprosy detskoy dietologii [Problems of Pediatric Nutrition]. 2017; 15 (2): 42–4. DOI: https://doi.org/10.20953/1727-5784-2017-2-42-44. (in Russian)

4. Zvyagin A.A., Bavykina I.A.. Nutritional approaches in treatment of autism spectrum disorders in children. Pediatriya. Zhurnal imeni G.N. Speranskogo [Pediatrics. Journal named after G.N. Speransky]. 2019; 98 (6): 171–6. DOI: https://doi.org/10.24110/0031-403X-2019-98-6-171-176 (in Russian)

5. Degterev D.А., Damulin I.V., Parfenov A.I. Neurological disorders associated with gluten sensitivity. Terapevticheskiy arkhiv [Therapeutic Archive]. 2017; 89 (2): 99–102. DOI: https://doi.org/10.17116/terarkh201789299-102 (in Russian)

6. Ivanova D.V., Semina I.I., Ziganshin A.U. Somatic disorders in autism as one of the factors of behavior and social interaction disorders. Kazanskiy meditsinskiy zhurnal [Kazan Medical Journal]. 2019; 100 (4): 689–94. DOI: https://doi.org/10.17816/kmj2019-689 (in Russian)

7. Chesnokova E.A., Sarycheva N.Yu., Dubynin V.A., Kamensky A.A. Opioid peptides obtained with food and their influence on the nervous system. Uspekhi fiziologicheskikh nauk [Advances in the Physiological Sciences]. 2015; 46 (1): 22–46. (in Russian)

8. Trivedi M.S., Shah J.S., Mughairy S.A., Hodgson N.W., Simms B., et al. Food-derived opioid peptides inhibit cysteine uptake with redox and epigenetic consequences. J Nutr Biochem. 2014; 25 (10): 1011–8. DOI: https://doi.org/10.1016/j.jnutbio.2014.05.004

9. Poletaev A.B., Poletaeva A.A., Khmel’nitskaya A.V. Changes in the opiate system in children suffering from autism. possible causes and consequences. Klinicheskaya patofiziologiya [Clinical Pathophysiology] 2016; 22 (1): 48–54. (in Russian)

10. Sun Z., Cade R. Findings in normal rats following administration of gliadorphin-7 (GD-7). Peptides. 2003; 24 (2): 321–4. DOI: https://doi.org/10.1016/s0196-9781(03)00043-3

11. Sun Z., Cade J.R., Fregly M.J., Privette R.M. β-Casomorphin induces fos-like immunoreactivity in discrete brain regions relevant to schizophrenia and autism. Autism. 1999; 3 (1): 67–83. DOI: https://doi.org/10.1177/1362361399003001006

12. Sokolov O.Yu., Kost N.V., Andreeva O.O., Korneeva E.V., Meshavkin V.K., Tarakanova Yu.N., et al. Possible role of casomorphins in the pathogenesis of autism. Psikhiatriya [Psychiatry]. 2010; (3): 29–35. (in Russian)

13. Jarmołowska B., Bukało M., Fiedorowicz E., Cieślińska A., Kordulewska N.K., Moszyńska M., et al. Role of milk-derived opioid peptides and proline dipeptidyl peptidase-4 in autism spectrum disorders. Nutrients. 2019; 11 (1): 87. DOI: https://doi.org/10.3390/nu11010087

14. Hunter L.C., O’Hare A., Herron W.J., Fisher L.A., Jones G.E. Opioid peptides and dipeptidyl peptidase in autism. Dev Med Child Neurol. 2003; 45 (2): 121–8. PMID: 12578238.

15. D’Eufemia P., Celli M., Finocchiaro R., Pacifico L., Viozzi L., Zaccagnini M., et al. Abnormal intestinal permeability in children with autism. Acta Paediatr. 1996; 85 (9): 1076–9. DOI: https://doi.org/10.1111/j.1651-2227.1996.tb14220.x

16. Khavkin A.I., Zhirnova S.А., Novikova V.P. The biological and clinical role of intestinal fatty acid-binding protein in clinical practice. Voprosy detskoy dietologii [Problems of Pediatric Nutrition]. 2020; 18 (1): 56–62. DOI: https://doi.org/10.20953/1727-5784-2020-1-56-62 (in Russian)

17. Zvyagin A.A., Bavykina I.A., Nastausheva T.L., Bavykin D.V. Intestinal fatty acid binding protein as the promising marker of small intestine permeability. Rossiyskiy vestnik perinatologii i pediatrii [Russian Bulletin of Perinatology and Pediatrics]. 2020; 65 (6): 29–33. DOI: https://doi.org/10.21508/10274065-2020-65-6-29-33 (in Russian)

18. Vreugdenhil A.C., Wolters V.M., Adriaanse M.P., Van den Neucker A.M., van Bijnen A.A., Houwen R., et al. Additional value of serum I-FABP levels for evaluating celiac disease activity in children. Scand J Gastroenterol. 2011; 46 (12): 1435–41. DOI: https://doi.org/10.3109/00365521.2011.627447

19. Adriaanse M.P., Tack G.J., Passos V.L., Damoiseaux J.G., Schreurs M.W., van Wijck K., et al. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment Pharmacol Ther. 2013; 37 (4): 482–90. DOI: https://doi.org/10.3109/00365521.2011.627447

20. Adriaanse M.P.M., Mubarak A., Riedl R.G., Ten Kate F.J.W., Damoiseaux J.G.M.C., Buurman W.A., et al.; Celiac Disease Study Group. Progress towards non-invasive diagnosis and follow-up of celiac disease in children; a prospective multicentre study to the usefulness of plasma I-FABP. Sci Rep. 2017; 7 (1): 8671. DOI: https://doi.org/10.1038/s41598-017-07242-4

21. Rubenstein E., Schieve L., Bradley C., DiGuiseppi C., Moody E., Thomas K., et al. The prevalence of gluten free diet uses among preschool children with autism spectrum disorder. Autism Res. 2018; 11 (1): 185–93. DOI: https://doi.org/10.1002/aur.1896

22. Ghalichi F., Ghaemmaghami J., Malek A., Ostadrahimi A. Effect of gluten free diet on gastrointestinal and behavioral indices for children with autism spectrum disorders: a randomized clinical trial. World J Pediatr. 2016; 12 (4): 436–42. DOI: https://doi.org/10.1007/s12519-016-0040-z

23. De Magistris L., Familiari V., Pascotto A., Sapone A., Frolli A., Iardino P., et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr. 2010; 51: 418–24. DOI: https://doi.org/10.1097/MPG.0b013e3181dcc4a5

24. Wang X., Niu Y., Yue C.X., Fu S., Wang R.T. Increased ileal bile acid binding protein and galectin-9 are associated with mild cognitive impairment and Alzheimer’s disease. J Psychiatr Res. 2019; 119: 102–6. DOI: https://doi.org/10.1016/j.jpsychires.2019.10.002/

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

SCImago Journal & Country Rank
Scopus CiteScore
CHIEF EDITOR
CHIEF EDITOR
Viktor A. Tutelyan
Full Member of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor, Scientific Director of the Federal Research Centre of Nutrition, Biotechnology and Food Safety (Moscow, Russia)

Journals of «GEOTAR-Media»